Literature DB >> 2023212

Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study.

M Wijnands1, P van Riel, M van 't Hof, F Gribnau, L van de Putte.   

Abstract

The longterm use of nonsteroidal antiinflammatory drugs (NSAID) was studied in a consecutive sample of 148 patients with recently diagnosed rheumatoid arthritis. A survival analysis was done in which treatment terminations due to side effects and to insufficient therapeutic effect were used as index causes. Cumulative drug 'survival' of indomethacin with treatment terminations due to untoward reactions as endpoints was significantly less compared to naproxen and diclofenac (p less than 0.001). No significant difference with termination due to lack of efficacy as index cause was observed (p greater than 0.90). No influence of sex or age on the drug survival with the different endpoints mentioned above could be established.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2023212

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.

Authors:  Juul M P A van den Reek; Wietske Kievit; Robert Gniadecki; Jelle J Goeman; Jeffrey Zweegers; Peter C M van de Kerkhof; Marieke M B Seyger; Elke M G J de Jong
Journal:  J Invest Dermatol       Date:  2015-07       Impact factor: 8.551

2.  Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia.

Authors:  K J Skeith; M S Hussain; R T Coutts; C Ramos-Remus; J A Avina-Zubieta; A S Russell
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

3.  Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis.

Authors:  E Martín-Mola; J Gijón-Baños; J J Ansoleaga
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 4.  COX-2 inhibitors in rheumatoid arthritis.

Authors:  J S Sundy
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.